Stephanie Nahas-Geiger, MD
Neurology · Philadelphia, PANPI 1033265004
Payments from drug & device makers
Across 1,188 payments — averaging $737.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$293K
- Lilly USA, LLC$218K
- Teva Pharmaceuticals USA, Inc.$210K
- Amgen$44K
- Pfizer$29K
- Lundbeck LLC$26K
- plus $55K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 424 | $293,349 |
| Lilly USA, LLC | 304 | $217,543 |
| Teva Pharmaceuticals USA, Inc. | 137 | $210,428 |
| Amgen | 67 | $44,283 |
| Pfizer | 44 | $28,930 |
| Lundbeck LLC | 33 | $26,228 |
| Amneal Pharmaceuticals LLC | 12 | $11,186 |
| H. Lundbeck A S | 2 | $10,625 |
| Biodelivery Sciences International, Inc. | 15 | $9,347 |
| Axsome Therapeutics, Inc. | 12 | $6,901 |
| Supernus Pharmaceuticals, Inc. | 61 | $5,669 |
| Tonix Medicines, Inc. | 5 | $3,778 |
| Novartis | 24 | $3,026 |
| Biohaven Pharmaceuticals, Inc. | 5 | $2,754 |
| Bausch Health US, LLC | 1 | $625 |
| Impel Pharmaceuticals Inc. | 9 | $442 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $241 |
| Eli Lilly | 5 | $214 |
| Biotissue Holdings Inc. | 1 | $111 |
| Upsher-smith Laboratories LLC | 5 | $91 |
| Collegium Pharmaceutical, Inc. | 4 | $57 |
| Biogen | 1 | $30 |
| Ipsen Biopharmaceuticals, Inc | 2 | $27 |
| Eisai Inc. | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Impel Pharmaceuticals LLC | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Promius Pharma LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $14 |
How this compares
$876,019 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Philadelphia
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
- Andres Deik Acosta MadiedoPhiladelphia$1.8M
- Michael SperlingPhiladelphia$1.7M
- Sanjeev VaishnaviPhiladelphia$1.6M
- Andrew SiderowfPhiladelphia$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.